Clinical Trial Update: Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, tolerability, and antiviral activity of Selgantolimod (GS-9688) in viremic adults with chronic hepatitis B who are not on treat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• GS-9688 (Selgantolimod)
• Selgantolimod (Selgantolimod)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis B | Phase 2 | Status: COMPLETED | Results posted: 2021-01-06